Gilead Sciences Inc. NASDAQGILD said it is stopping a Phase IIIII study of ulcerative colitis candidate GS5745 based on an interim futility analysis that showed "insufficient evidence of a treatment benefit" in either of two dose groups.Gilead sa...
↧